Evidence map›Paper›PMID 42493730›Full record

ArticleJournal of thrombosis and thrombolysis2026

Pulmonary vascular resistance at hospital admission is associated with early mortality in patients with intermediate-to-high-risk acute pulmonary embolism.

Leslie Marisol González-Hermosillo, Marlene Monserrat Juárez, Elizabeth Ramírez, Yatzin Martínez-Izguerra, Leonardo Lozano-Carrillo, Dulce Iliana Navarro-Vergara, María Berenice Torres-Rojas, Marisol García-Cesar, Javier Gaytán-Cervantes, Guillermo Cueto-Robledo and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of thrombosis and thrombolysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Leslie Marisol González-HermosilloLaboratorio de Inmunometabolismo, Dirección de Investigación, Hospital General de México "Dr. Eduardo Liceaga", 06726, Mexico City, Mexico.
Marlene Monserrat JuárezLaboratorio de Inmunometabolismo, Dirección de Investigación, Hospital General de México "Dr. Eduardo Liceaga", 06726, Mexico City, Mexico.
Elizabeth RamírezLaboratorio de Inmunometabolismo, Dirección de Investigación, Hospital General de México "Dr. Eduardo Liceaga", 06726, Mexico City, Mexico.
Yatzin Martínez-IzguerraLaboratorio de Inmunometabolismo, Dirección de Investigación, Hospital General de México "Dr. Eduardo Liceaga", 06726, Mexico City, Mexico.
Leonardo Lozano-CarrilloLaboratorio de Inmunometabolismo, Dirección de Investigación, Hospital General de México "Dr. Eduardo Liceaga", 06726, Mexico City, Mexico.
Dulce Iliana Navarro-VergaraClinica de Enfermedad Vascular Pulmonar, Hospital General de México "Dr. Eduardo Liceaga", 06726, Mexico City, Mexico.
María Berenice Torres-RojasClinica de Enfermedad Vascular Pulmonar, Hospital General de México "Dr. Eduardo Liceaga", 06726, Mexico City, Mexico.
Marisol García-CesarClinica de Enfermedad Vascular Pulmonar, Hospital General de México "Dr. Eduardo Liceaga", 06726, Mexico City, Mexico.
Javier Gaytán-CervantesDivisión de Desarrollo de la Investigación en Salud, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, 06720, Mexico City, Mexico.
Guillermo Cueto-RobledoClinica de Enfermedad Vascular Pulmonar, Hospital General de México "Dr. Eduardo Liceaga", 06726, Mexico City, Mexico.
Galileo EscobedoLaboratorio de Inmunometabolismo, Dirección de Investigación, Hospital General de México "Dr. Eduardo Liceaga", 06726, Mexico City, Mexico. gescobedog@msn.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute pulmonary embolism (PE) is a critical disease with a high 30-day mortality rate in intermediate-to-high-risk (IHR) patients. Herein, we prospectively enrolled 117 patients with IHR-PE and recorded demographic, clinical, and biochemical parameters from electronic records, as well as hemodynamic variables acquired by right-heart catheterization during catheter-directed thrombolysis. After a 6-month follow-up, we retrospectively analyzed all variables. Most hemodynamic parameters were significantly higher in patients who subsequently died within the first 30 days after admission than in patients who survived, especially pulmonary vascular resistance (PVR) (9.6 ± 3.3 versus 5.5 ± 3.1, p = 0.002, respectively). In fact, PVR ≥ 6.55 Wood units (WU) was an accurate predictor of 30-day mortality, with an area under the receiver operating characteristic curve of 0.85 (95% Confidence Interval, 0.71-0.97; p = 0.007), a sensitivity of 100%, and a specificity of 70%. Our findings emphasize the urgency of assessing hemodynamic parameters in all IHR-PE patients and prompt discussion of the benefit-risk balance of right-heart catheterization in IHR-PE.

Indexed as

30-day mortalityPulmonary embolismPulmonary vascular resistanceRight-heart catheterization

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.